← Oncology Approval Tracker

FDA DECISION ·

Hercessi

trastuzumab-strf · Accord BioPharma

Biosimilar approvalBiosimilarBreast and gastric or gastroesophageal junction cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Trastuzumab biosimilar for labeled HER2-overexpressing adjuvant and metastatic breast cancer uses and first-line metastatic gastric or gastroesophageal junction adenocarcinoma with designated chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The biosimilar adds another IV trastuzumab supply option for established HER2-positive indications.

What research teams should watch

Retain the HER2 diagnostic result and standardize cardiac monitoring and product traceability across ordering and dispensing.

PRIMARY RECORDS

Sources